Strategic Access Partner to
Pharma, Biotech and Investors
Driving Asset Evolutions and Pipeline Optimization
Strategies for better Health and Maximised Value
SERVICES
For Pharma and Biotech
Your Partners in Strategy Development, Value Assessments and Insights Generation
BUSINESS DEVELOPMENT
Accurate evaluations for commercial value are essential for informed decision-making and commercial success!
Are you convinced you base your BD decisions on best in class commercial evaluations?
INSIGHTS GENERATION
Strategies are only as strong as the insights they
are based on. Quality in, quality out!
Are you confident that the insights you base
your strategies on are accurate and strong?
PIPELINE OPTIMIZATION
Early strategic patient access and price considerations are crucial for unlocking untapped value of assets in your organization!
Are you certain that you have captured maximum value of your pipeline?
CAPABILITY ELEVATION
Price and access achievements are only as good as the talents and capability of your organization!
Are you convinced that skills and talents are best in class in your pricing and patient access teams?
ABOUT US
We understand that there is a human consequence to any price and and access decision made by life science companies and payers.
We strive to deliver optimal and balanced solutions considering both patient access, returns on R&D investments and the needs of health-care authorities, systems, and payers.
Our strong expertise in pricing and patient access, combined
with our tenacious mindset, drive us to find solutions and
persevere through tough challenges in close collaboration with you.
Access Elevate is a global force boasting a vast payer and consultancy network with presence and expertise worldwide.
Although working apart we always present as one unit.
WHY WORK WITH US
We are your exclusive partner for pricing and
patient access, for pipeline and business development value optimization and returns
Solution-oriented approach
As the only consulting firm exclusively focused on market access and pricing for business development, commercial due diligence, and pipeline strategy, we bring unparalleled expertise and insights to help our clients navigate complex decisions with confidence
We combine AI-powered research platforms with a carefully curated global payer network built over many years. This unique blend of technology and human expertise ensures our clients receive precise, actionable insights that drive smarter, faster strategic decisions and solid evaluations.
We believe every challenge has a path forward. Guided by a principle of finding solutions never taking ‘no’ for an answer, we work relentlessly to deliver strategies that unlock value and enable success, even in the most complex situations.
Unmatched Specialization
Data-Driven Precision, Human Expertise
Every solution we provide is backed by seasoned experts dedicated to crafting
creativeand viable strategies tailored to your specific needs
OUR TEAM
Meet our Founder & Partners
Pernille Storm
Founder and managing partner
20+ years industry experience and significant academic contributions.
Proven track record in pricing and access, with VP-level strategic leadership,
oversight of global market access and pricing teams, and hands-on experience in
local affiliate execution.
With extensive experience in conducting over 200 business development evaluations and pipeline access strategy optimizations, she is recognized as a preeminent leader in the field.
Her exceptional expertise, resilience and strategic vision have significantly advanced the projects and outcomes she has worked on.
.png?etag=undefined&sourceContentType=image%2Fpng&ignoreAspectRatio&resize=371%2B147){kind=logo}
Pricia is a Copenhagen-based company that support pharmaceutical and biotechnology companies with high impact pricing strategies, innovative global pricing solutions and price management. Founder Paw Trebbien brings extensive experience from senior global pricing and market access roles. The company provides advanced, algorithm-driven pricing models that enable precise forecasting, real-time impact simulations, and robust mitigation planning.
Enlightenment Bioconsult is a U.S.-based consultancy with deep expertise in the complexities of the American payer landscape. The company is led by Dr. Ed Pezalla,
a recognized thought leader in payer strategy . As the former Vice President of Pharmaceutical Policy and Strategy at Aetna, and a current member of the EXCITE International Payers' Advisory Committee, Dr. Pezalla brings unparalleled insight and strategic vision his consultancy work for biopharmaceutical firms on access, technology assessment, and drug evaluation in the US market.
Inbeeo is a London-based company that delivers tailor-made solutions to address
the toughest market access challenges faced by pharmaceutical companies and medical technology suppliers. Led by seasoned pricing and access expert Hervé Lillieu, Inbeoo brings a uniquely skilled team combining deep experience, strategic insight, and proven expertise to unlock the full value of health technologies for patients, payers, physicians, and healthcare systems.
A Few Selected Case Studies
BUSINESS CASE VALIDATION
COMMERCIAL DUE DILIGENCE
INDICATION SELECTION
PIPELINE OPTIMIZATION
Client Situation
A privately owned European biotech company was preparing to update its business case for a Parkinson’s disease asset ahead of a key shareholder meeting and ongoing licensing discussions.
Challenge
The company wanted to pressure-test the global commercial forecast delivered by a leading consultancy 18 months earlier. Several assumptions appeared questionable, and critical new information about the asset had since emerged.
Our Approach
We validated and refined business case assumptions through targeted desk research and a select number of payer interviews. This approach sharpened pricing, market access, and market share forecasts.
Impact
Our analysis generated critical insights that led to concrete adaptations of the commercial case. These refinements strengthened the reliability of the asset’s value as presented to owners and potential partners.
Client Situation
A European public pharmaceutical company was evaluating multiple M&A opportunities to strengthen its pipeline. One was a late-stage asset in rare childhood epilepsy.
Challenge
The acquisition decision hinged in large part on the market access and pricing potential across several indications and geographies, making robust validation essential.
Our Approach
We conducted a comprehensive landscape analysis, reviewing competitor HTA outcomes, pricing benchmarks, and all due diligence materials, including formal HTA advice notes and payer research. Additional payer interviews were carried out to stress-test assumptions and model alternative scenarios.
Impact
Our work delivered a robust analysis with a clear recommendation, enabling the client to move forward with confidence.
Client Situation
A European mid-sized pharmaceutical company was evaluating a pre-clinical molecule to determine which indications held the greatest commercial potential.
Challenge
Research and clinical teams had identified 150 possible indications. Only three could be prioritized for further development planning.
Our Approach
We first assessed price potential, market size, and overall opportunity, which enabled a rapid de-selection of the majority of indications. A focused deep dive into 10 high-potential areas followed, including detailed HTA analyses, analogue research, payer interviews in the US and Europe, and market share modeling. From this, the three most promising indications were selected, along with a recommended order of entry.
Impact
Our conclusions directly guided clinical development planning and asset valuation, ensuring resources were focused on the highest-value opportunities.
Client Situation
A European public pharmaceutical company was evaluating a pre-clinical molecule to determine which indications held the greatest commercial potential.
Challenge
Research and clinical teams had identified 150 possible indications. Only three could be prioritized for further development planning.
Our Approach
We first assessed price potential, market size, and overall opportunity, which enabled a rapid de-selection of the majority of indications. A focused deep dive into 10 high-potential areas followed, including detailed HTA analyses, analogue research, payer interviews in the US and Europe, and market share modeling. From this, the three most promising indications were selected, along with a recommended order of entry.
Impact
Our conclusions directly guided clinical development planning and asset valuation, ensuring resources were focused on the highest-value opportunities.
Contact Us
FIND US
GET IN TOUCH